All In Biotech

Drug Trial Radar · NCT05687136

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination With the ATR Inhibitor Tuvusertib (M1774)

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Jun 7, 2024

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Sponsor type
NIH
First posted
Jan 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial tests the safety, side effects and best dose of peposertib (M3814) in combination with tuvusertib (M1774) in treating patients with solid tumors that have spread to other places in the body (advanced). Peposertib and tuvusertib stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Advanced Malignant Solid Neoplasm
  • Metastatic Malignant Solid Neoplasm
  • Unresectable Malignant Solid Neoplasm

Interventions

  • Biopsy ProcedureProcedure

    Undergo tissue biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • PeposertibDrug

    Given PO

  • Positron Emission TomographyProcedure

    Undergo PET

  • TuvusertibDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicityTime frame: Up to 28 days
  2. Incidence of adverse eventsTime frame: Up to week 12

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Institute Developmental Therapeutics Clinic

    Bethesda, Maryland · Recruiting

  • National Institutes of Health Clinical Center

    Bethesda, Maryland · Active not recruiting

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • NYU Langone Hospital - Long Island

    Mineola, New York · Recruiting

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.